当前位置: 首页 > 期刊 > 《中国当代医药》 > 2018年第16期
编号:13297769
心房颤动治疗进展(5)
http://www.100md.com 2018年6月5日 《中国当代医药》 2018年第16期
     [24]Steinberg JS,Sadaniantz A,Kron J,et al.Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study[J].Circulation,2004,109(16):1973-1980.

    [25]Hakalahti A,Biancari F,Nielsen JC,et al.Radiofrequency ablation vs.antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation:systematic review and meta-analysis[J].Europace,2015,17(3):370-378.

    [26]Haissaguerre M,Jais P,Shah DC,et al.Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins[J].N Engl J Med,1998,339(10):659-666.

    [27]Ganesan AN,Shipp NJ,Brooks AG,et al.Long-term Outcomes of Catheter Ablation of Atrial Fibrillation:a Systematic Review and Meta-analysis[J].J Am Heart Assoc,2013,2(2):e4549.

    [28]Bunch TJ,Crandall BG,Weiss JP,et al.Patients treated with catheter ablation for atrial fibrillation have long-term rates of death,stroke,and dementia similar to patients without atrial fibrillation[J].J Cardiovasc Electrophysiol,2011,22(8):839-845.

    [29]Calkins H,Kuck KH,Cappato R,et al.2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation:recommendations for patient selection,procedural techniques,patient management and follow-up,definitions,endpoints,and research trial design[J].Europace,2012,14(4):528-606.

    (收稿日期:2018-01-15 本文編辑:闫 佩), 百拇医药(王玉兵 殷跃辉)
上一页1 2 3 4 5